Brief: Trevi Therapeutics Q3 Net Income USD -11.802 Million
13/11/2025 21:05
Nov 13 (Reuters) - Trevi Therapeutics Q3 operating expenses USD 13.916 million. Q3 EPS USD -0.08 Q3 pretax profit USD -11.817 million Q3 income from operations USD -13.916 million
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million